To: Susan Saline who wrote (21830 ) 1/6/2000 9:01:00 AM From: Volsi Mimir Respond to of 53068
NBIX should have a good day today... deal with Japanese company on Diabetes APL tech... excerpt Neurocrine Biosciences, Inc. (Nasdaq: NBIX - news) announced today that it has signed an exclusive agreement with Taisho Pharmaceutical Co. LTD providing Taisho an option to obtain European and Asian commercialization rights for Neurocrine's altered peptide ligand (APL) for diabetes (NBI-6024). Neurocrine will retain all rights in the rest of the world, including North America. Taisho and Neurocrine will form a steering committee to coordinate the worldwide development of NBI 6024. The approximate value of the collaboration will be $45 million, which includes licensing and option fees, payments for certain development and regulatory milestones, and reimbursement of 50% of the worldwide development expenses. In addition, Neurocrine will receive royalties on product sales in Europe and Japan. According to Jean-Francois Bach, M.D., Professor and Head, Department of Clinical Immunology, Hospital Necker, ``New treatments, like the altered peptide ligand (APL) approach may offer great therapeutic potential in the intervention of this devastating autoimmune disease.' Dr. Bach is a worldwide leader in clinical autoimmune disease research, who, for numerous years, has investigated the pathogenesis, genetics, prevention and treatment of IDDM. guys at NBIX board like itSubject 6731 which brings this fact : I base my decisions on some of the people there (Harmon, Zuanic, WTDEC, many more) I am learning slowly...Krist you have to have a Phd just to figure out what they say sometimes...So PLEASE do your DD or follow/read these guys .. I bring these 2 stocks(TTP, NBIX) as speculative positive companies...one ruling by the almighty gods at FDA spikes this one way or the other..